51. (Journal Article): Pancreatic Head Mass: What Can Be Done? Classification: The Clinical Point of View

Pulay I, Tihanyi TF, Flautner L
 
ABSTRACT: Surgeons frequently find pancreatic head mass when operating. The obvious difficulty is to make the correct preoperative differential diagnosis between chronic pancreatitis and pan...

52. (Journal Article): When oral agents fail: practical barriers to starting insulin.

Korytkowski M
 
ABSTRACT: Insulin therapy has proven benefits in Type 2 diabetes patients when combination therapy has failed. However, there is some reluctance by both patients and healthcare professionals...

53. (Journal Article): An international study of physiological insulin resistance to insulin use among persons with diabetes.

Peyrot M, Mathews DR, Snoek FJ, Calogiuri R, Kleinebreil L, Rubin R, Ishii H, Lauritzen T, Geelhoed-Duijvestijn PH, Skovlund SE

54. (Journal Article): The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

Harder H, Nielsen L, Tu DT, Astrup A
 
ABSTRACT: OBJECTIVE: Glucagon-like peptide (GLP)-1 is a gut hormone that exerts incretin effects and suppresses food intake in humans, but its therapeutic use is limited due to its short hal...

55. (Journal Article): Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD
 
ABSTRACT: PURPOSE: The pharmacology and tolerability of exenatide in patients with type 2 diabetes mellitus were studied. METHODS: Two randomized, single-blind, placebo-controlled studies we...

56. (Journal Article): Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.

Deacon CF, Holst JJ
 
ABSTRACT: n.a.

57. (Journal Article): Glucagon-like peptide-l (7-37) suppresses hyperglyeaemia in rats.

Hendrick GK, Gjinovci A, Baxter LA, Mojsov S, Wollheim CB, Habener JF, Weir GC
 
ABSTRACT: Glucagon-like peptide-(GLP) I-(7-37) is an endogenous hormone that has recently been demonstrated to be a potent insulin secretagogue. In these studies, GLP was administered during...

58. (Journal Article): Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

Nauck MA, Wollschlager D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B
 
ABSTRACT: Intravenous glucagon-like peptide (GLP)-1 [7-36 amide] can normalize plasma glucose in non-insulin-dependent diabetic (NIDDM) patients. Since this is no form for routine therapeuti...

59. (Journal Article): Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives.

Meier JJ, Gallwitz B, Schmidt WE, Nauck MA
 
ABSTRACT: After ingestion of carbohydrate- and fat-rich meals, the incretin hormone glucagon-like peptide 1 (GLP-1) is secreted from the L-cells in the distal put into the circulation. Its m...

60. (Journal Article): Incretin mimetics as emerging treatments for type 2 diabetes.

Joy SV, Rodgers PT, Scates AC
 
ABSTRACT: OBJECTIVE: To review the physiology, pharmacology, and clinical efficacy of glucagon-like peptide (GLP-1) and the incretin mimetics exenatide and liraglutide in clinical studies. D...